Hence, future research determining individual ADA affinities from affected FD patients against the infused enzyme is now warranted to assess if individual differences might occur and if they affect treatment outcomes by reduced AGAL inhibition, while decreasing affinities over longitudinal measures might show a beginning of tolerization of the patient. This evidence concerns the gene ADA and Fabry disease.